Takeda has returned to back the cancer therapeutics developer’s series D round after committing $120m in equity and milestone financing just over 18 months ago.
Branding services provider Tailor Brands raised $50m in a GoDaddy-led series C round while Orix is set to exit hiring software developer PandoLogic in a $150m acquisition.
The Corteva, Novartis, AbbVie and Heritage Medical Systems-backed cancer therapy developer priced a $304m initial public offering at the top of its range.
Baidu Ventures and AliHealth both invested in a series C round for the genome sequencing technology provider, which counts BGI as an existing investor.
Unilever Ventures and Sistema Asia Capital have backed the health and fitness app developer’s latest round, which took its overall funding past $100m.
Several corporates backed a $68m series D round for microbiome drug developer Vedanta Biosciences while grooming brand owner Pangaea raised the same amount from investors including Unilever.
TMRW Life Sciences is eyeing a global expansion of its frozen egg and embryo management services with new capital from investors including GV.
Danaher is in line to exit proteomics platform developer IsoPlexis in a Nasdaq Global Market offering with a $100m placeholder target.
Nan Fung and Lam Research are set to exit the DNA sequencing technology developer in an $800m acquisition by market peer Pacific Biosciences.
Panakès Partners is now targeting a final close upwards of $210m for its Purple Fund, which has reached its Menarini-backed first close.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
